Moreover, CDK9 inhibitors downregulate the inhibitor of apoptosis-stimulating protein of p53 (iASPP), restoring p53 tumor-suppressing functions and opening a new perspective for the treatment of patients with loss of p53 function [25] (Fig. 2). The gene discussed is TP53; the disease is neoplasm.